Sputnik V maker Dr. Reddy’s initiates process for Emergency Use Authorization
[ad_1]
Sputnik V is certainly one of solely three vaccines on the earth with an efficacy of 91.6% and has most authorizations granted with 26 international locations globally, says firm.
Dr. Reddy’s Laboratories Ltd. on Friday announced that it had initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of human adenoviral vector-based platform vaccine candidate Sputnik V.
“As part of the review process, Dr. Reddy’s will present the safety profile of the phase-two study, and interim data of the phase-three study, which is expected to complete by 21st February 2021”, famous a launch issued by the corporate.
Also learn: Coronavirus | Sputnik V COVID-19 vaccine shows interim efficacy of 91%
G V Prasad, Co-chairman and Managing Director of Dr. Reddy’s Laboratories, mentioned, “The efficacy of Sputnik V was reported to be 91.6 % by the Lancet, which is an impressive development in the fight against COVID-19. The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India.”
Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia on August 11, 2020 and have become the world’s first registered vaccine in opposition to COVID-19 based mostly on the human adenoviral vector platform.
Read: Sputnik V vaccine launch likely in March
“More than 250 clinical studies over two decades have proven the safety, efficacy, and lack of negative long-term effects of adenoviral vaccines. Sputnik V is one of only three vaccines in the world with an efficacy of 91.6% and has most authorizations granted with 26 countries globally. The vaccine has already been administered to more than 2 million people worldwide,” the discharge said.
It additional mentioned that in September 2020, Dr. Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the scientific trials of Sputnik V and for its distribution rights in India.
“The vaccine is currently undergoing the phase three clinical trial in India. Sputnik V has demonstrated an efficacy rate of 91.6% in the interim analysis of the phase 3 clinical trial, which included data on 19,866 volunteers in Russia, who received both the first and second doses of the vaccine. Sputnik V maintained a consistent efficacy at 91.8% even among the group of 2,144 volunteers over 60 years old,” mentioned the corporate.
Dear subscriber,
Thank you!
Your help for our journalism is invaluable. It’s a help for fact and equity in journalism. It has helped us maintain apace with occasions and happenings.
The Puucho has all the time stood for journalism that’s within the public curiosity. At this troublesome time, it turns into much more essential that now we have entry to data that has a bearing on our well being and well-being, our lives, and livelihoods. As a subscriber, you aren’t solely a beneficiary of our work but in addition its enabler.
We additionally reiterate right here the promise that our workforce of reporters, copy editors, fact-checkers, designers, and photographers will ship high quality journalism that stays away from vested curiosity and political propaganda.
[ad_2]
